drugset
drugset / Trial / NCT03235778

A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China

NCT03235778 ↗

Phase 1 Completed 58 enrolled Yiling Pharmaceutical Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 2. To evaluate the pharmacokinetic characteristics in healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose

Timeline

Start
2017-07-17
Primary completion
2018-03-19
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Felbinac Trometamol Unknown 11.78 mg Intravenous
Subject Felbinac Trometamol Unknown 23.56 mg Intravenous
Subject Felbinac Trometamol Unknown 47.13 mg Intravenous
Subject Felbinac Trometamol Unknown 94.25 mg Intravenous
Subject Felbinac Trometamol Unknown 164.92 mg Intravenous
Subject Felbinac Trometamol Unknown 259.16 mg Intravenous
Subject Felbinac Trometamol Unknown 377 mg Intravenous

Indications

No indication recorded.